stocks logo

INTS

Intensity Therapeutics Inc
$
0.325
0(0.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.3382
Open
0.330
VWAP
0.33
Vol
6.14M
Mkt Cap
8.47M
Low
0.31925
Amount
2.03M
EV/EBITDA(TTM)
--
Total Shares
13.71M
EV
7.55M
EV/OCF(TTM)
--
P/S(TTM)
--
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Show More
3 Analyst Rating
up Image
1053.85% Upside
Wall Street analysts forecast INTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTS is 3.75 USD with a low forecast of 3.50 USD and a high forecast of 4.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
up Image
1053.85% Upside
Current: 0.325
sliders
Low
3.50
Averages
3.75
High
4.00
Alliance Global Partners
Buy
downgrade
2025-05-22
Reason
Alliance Global Partners lowered the firm's price target on Intensity Therapeutics to $3.50 from $8.50 and keeps a Buy rating on the shares. The price target reduction reflects the trial delay for INT230-6 for soft tissue sarcoma, the analyst tells investors in a research note. The trial is being paused until further notice due to funding constraints, and the firm believes it will take a major funding event to get it back on track.
Brookline
analyst
Buy -> Hold
downgrade
2025-05-19
Reason
Brookline downgraded Intensity Therapeutics to Hold from Buy and suspended the firm's price target pending visibility into additional funding. A global Phase 3 open label, randomized, superiority trial is ongoing in metastatic sarcoma, evaluating INT230-6 monotherapy as an intratrumoral treatment compared to the standard of care in second and third line treatment in soft tissue sarcoma subtypes, notes the analyst, who points out that enrollment completion is expected in the first half of 2026, with data readouts expected based on the number of deaths in the trial.
Alliance Global Partners
James Molloy
Strong Buy
Initiates
$8.5
2025-01-13
Reason
Alliance Global Partners initiated coverage of Intensity Therapeutics with a Buy rating and $8.50 price target. Intensity is developing INT230-6, a Phase 3 asset that both decreases the tumor burden while also activating an increased immune system response to better recognize and target the cancer, for advanced soft tissue sarcoma and triple negative breast cancer. The firm values INT230-6 for STS at $6 per share, INT230-6 for TNBC at $2 per share, and the remaining compounds and cash at 50c per share, the analyst noted.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$5
2024-11-21
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Initiates
$5
2024-10-31
Reason

Valuation Metrics

The current forward P/E ratio for Intensity Therapeutics Inc (INTS.O) is -0.49, compared to its 5-year average forward P/E of -3.59. For a more detailed relative valuation and DCF analysis to assess Intensity Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.59
Current PE
-0.49
Overvalued PE
-1.26
Undervalued PE
-5.91

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q1
YoY :
-28.44%
-3.39M
Operating Profit
FY2025Q1
YoY :
-27.29%
-3.35M
Net Income after Tax
FY2025Q1
YoY :
-35.29%
-0.22
EPS - Diluted
FY2025Q1
YoY :
-54.44%
-1.99M
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

INTS News & Events

Events Timeline

2025-06-30 (ET)
2025-06-30
08:06:08
Intensity Therapeutics: INT230-6 achieved 100% complete response rate in MPNST
select
2025-06-12 (ET)
2025-06-12
05:55:01
Intensity Therapeutics 6.675M share Spot Secondary priced at 30c
select
2025-06-11 (ET)
2025-06-11
16:12:46
Intensity Therapeutics announces common stock offering, no amount given
select
Sign Up For More Events

News

5.0
06-30PRnewswire
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
9.0
06-30PRnewswire
Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)
5.0
06-20Newsfilter
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
Sign Up For More News

FAQ

arrow icon

What is Intensity Therapeutics Inc (INTS) stock price today?

The current price of INTS is 0.325 USD — it has increased 0 % in the last trading day.

arrow icon

What is Intensity Therapeutics Inc (INTS)'s business?

arrow icon

What is the price predicton of INTS Stock?

arrow icon

What is Intensity Therapeutics Inc (INTS)'s revenue for the last quarter?

arrow icon

What is Intensity Therapeutics Inc (INTS)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Intensity Therapeutics Inc (INTS)'s fundamentals?

arrow icon

How many employees does Intensity Therapeutics Inc (INTS). have?

arrow icon

What is Intensity Therapeutics Inc (INTS) market cap?